Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis - ONA

Links shared publicly online about this topic.

  • 356
    total visits

Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis - ONA

oncologynurseadvisor.com

The FDA has approved Actemra (tocilizumab; Genentech), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA), or Still--™s disease, in children 2 years.

View full resource at oncologynurseadvisor.com

Tags: Crohn's Disease Medication, Arthritis, Rheumatoid Arthritis Medication, Juvenile Rheumatoid Arthritis, Children's Health, FDA, Actemra, Genentech

  • Share

Most Recently Shared on April 18, 2011 at 4:12 pm By:

ONAcom OncologyNurseAdvisor

Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis http://goo.gl/fb/Fz9Ea

1 year ago...

Jab that ends the agony of childhood arthritis: New NHS treatment brings relief to nine in ten young patients | Mail Online

dailymail.co.uk — “NICE has approved RoActemra (tocilizumab) to treat systemic juvenile idiopathic arthritis (sJIA) which is currently incurable.View full resource at dailymail.co.uk

  • View Related
  • Share

Most Recently Shared on February 4, 2012 at 11:25 pm By:

DerekDowell Derek Dowell Patient Expert

Jab that ends the agony of childhood arthritis: New NHS treatment brings ... http://t.co/UNyqvFt2

3 months ago...

ACTEMRA (tocilizumab) | Rheumatoid Arthritis Treatment

actemra.com — “Find information about ACTEMRA, an FDA-approved treatment for rheumatoid arthritis. ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a Tumor Necrosis Factor (TNF) antagonist has been used and did not work well. ACTEMRA is used to treat people with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older. SoView full resource at actemra.com

  • View Related
  • Share

Most Recently Shared on January 20, 2012 at 3:35 pm By:

Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis - MPR

empr.com — “The FDA has approved Actemra (tocilizumab; Genentech), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA), or Still--™s disease, in children 2 years.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 18, 2011 at 4:11 pm By:

eMPR MPR Medical Publisher

MPR News: Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis: The FDA has approved Actemra (tocil... http://bit.ly/erCY89

1 year ago...

Advertisement